Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Pleural Mesothelioma

NCT04914897 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04914897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04914897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Pleural Mesothelioma
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Terminated
Start date
September 23, 2021
Completion date
October 17, 2024
Enrollment
106 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, pleural mesothelioma